Member Info for sharky007

looking good here, 110m shares mcap £2.5m tiny for an aim oilie.

early days, still very much under the radar.

I came late to the mosman party, haven't got much in there but its looking good all the same. hoping early adopters reap the benefits here. think doc and his connections at redhotstocks/shareprophets will be tipping this shortly. the herd hasn't arrived yet. ATVB everyone buying in today :)

think this one slipped under the net. 110m shares mcap £2.31m. assets in Zambia, oman, and Namibia. year high of 6.75p. GLA

yep this is about to take off. spread nice and tight now. 3.6p target short term. lock and load. ATB

110m shares, mcap £2.3m.

Moving up..

multibagger here. AR needs to keep this at .5p for 30 days to see his options. reckon this will hit 1p+ old money, £1+ new, II's were 4x oversubscribed so will be back for much more when name change takes effect.

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=12003804

NAV 9.68p 43% dscount

The June tip of the Month: Buy Vialogy at a 0.17p offer – one month target 0.255p to sell Not one but three members of the HotStockRockets team have interests in this stock but we will not sell until at least 24 hours after advising you to do so. And we reckon that if you buy today you will be making a 50% return within a month. Vialogy (LSE:VIY) is our tip of the month at a 0.17p offer. This AIM listed company used to be a total joke of a lifestyle company, pretending that it had new technology in oil. Thankfully at death’s door it was rescued by well-known turnaround/cash shell expert Adam Reynolds. The shares came back from suspension a couple of weeks ago as Reynolds announced a transformational RTO. That will be ratified at an EGM this Thursday which will also approve a 100 for 1 share consolidation (which will narrow the spread) and a change of name to Premaitha. The maths. The company raised £6.5 million at 0.11p. It also issued £10.5 million of shares at 0.11p to buy Premaitha. The shareholders of Premaitha are locked in and the placees are all institutional so can’t flip like a private investor and so are effectively locked in. The placing was FOUR times oversubscribed. Thus with another institutional placing done earlier this year by Reynolds the free float is sub 10%. The shares have been hit since the return from suspension by some in the free float selling ordinaries to pay for participation in a 1 for 4 open offer. There is now no time left for any more such flipping. The market capitalisation is now – at 0.17p to buy – £29 million and net cash is c£8 million. So how do you justify an EV of £21 million? Easy. 1. Management. The Premaitha team is headed up by an accomplished CEO Stephen Little but also has on board David Evans. Many years ago he turned Axis Shield from a penny stock into an £8 stock. He knows this industry and has a mass City following so we expect institutional buying post the EGM 2. The company is working on the final development and commercialisation of a non-invasive pre-natal screening test for Down’s syndrome developed by Premaitha. This is a massive market. Of course there are risks in medical technology but we back Evans and the size of this global market is estimated to be $4.2 billion. We are assured that Vialogy needs no more ash to get its product to market and you do not need much of a market share to justify the EV here. Reasons to buy now: 1. The shares have been depressed by small investors selling ordinaries to take up the open offer. That process is now over. 2. Management. Enough said. 3. Post EGM we expect institutional buying from those who were massively scaled back in the placing and there is a relatively small free float. 4. We expect that with a news blackout for several months there is a pipeline of RNS announcements which will start very soon after the EGM

David is an entrepreneurial accountant focusing on diagnostic and life science companies. He has a plethora of Chairman and Non Executive roles across the sector including Epistem Holdings plc, Omega Diagnostics Group plc, EKF Diagnostic Holdings plc and Scancell Holdings plc. David was the former Chairman of DxS and oversaw the acquisition by QIAGEN in 2009. He was the Joint MD of Axis Shield and was responsible for the merger. David holds an MBA from University of Dundee.

He is the former CEO of DxS, an innovator in the field of personalised medicine, developing and manufacturing companion diagnostics. DxS was funded with £3.5M in 2001 and was sold to QIAGEN BV in 2009 for £85M. That's a massive return on investment. This guy doesn't mess about, multibagger coming here. Buy and hold.

He is the former CEO of DxS, an innovator in the field of personalised medicine, developing and manufacturing companion diagnostics. DxS was funded with £3.5M in 2001 and was sold to QIAGEN BV in 2009 for £85M. That's a massive return on investment.

multibagger here guys, read Dr Stephen Little previous deal: Stephen is a successful serial biotechnology entrepreneur. He is the former CEO of DxS, an innovator in the field of personalised medicine, developing and manufacturing companion diagnostics. DxS was funded with £3.5M in 2001 and was sold to QIAGEN BV in 2009 for £85M. DxS pioneered the use of molecular diagnostic tests such as KRAS and EGFR mutation analysis to predict the use of novel cancer therapies. In 2009, DxS was acquired by QIAGEN and Stephen became Vice President of Personalised Healthcare, responsible for developing companion diagnostic partnerships with the pharma industry. Prior to his leading role at DxS, Stephen worked for 20 years in various senior positions in the diagnostic divisions of Astra Zeneca and ICI. He holds a PhD from Heriot-Watt University in Edinburgh. http://www.premaitha.com/company/the-team/27-company/the-team/management-team-and-directors/63-dr-stephen-little-chief-executive-officer-director

load up here guys, see this doing extremely well next week. calm before the storm. won't be many shares around. GLA

multibagger waiting to happen, directors will drive this to .5p per their options very quickly. Institutions loaded up. 55% shares not in public hands. anything around this SP is a giveaway imo.

Down's syndrome drug multibillion pound market, sure fire winner imo. placing 4 times oversubscribed. open offer expired yesterday so should go positive going forward. GLA

16.7 paid, buys coming in now. sneaky mm's

http://guerillainvesting.co.uk/2014/06/26/vialogy-im-in-for-a-spin/